hotspot -WSS

hotspot

author：focus 2025-09-28 12:10:25 - browse：2126

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Fauci’s Covid grilling leads GOP to weigh foreign research rules

WSS

How I ended up pumping milk in a bathroom stall at JPM 2024

How I ended up pumping milk in a bathroom stall at JPM 2024

GSK to buy asthma

HHS names first

FDA rejects Alnylam's heart disease treatment over insufficient data

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

hotspot

hotspot

hotspot

In Memoriam: Notable people who died in 2023

The future of health care in the House

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Liquid biopsy for lung cancer is launched by Delfi

State Dept. review finds Biden bears some blame for Afghanistan failures

Chemotherapy drug shortage eases slightly but still widespread

The cancer drug shortage isn’t new — and neither are the solutions

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

What does generative AI mean for health care? We asked experts

When women are denied an abortion, their children fare worse than peers

explore

Doulas covered by Medicaid under New York's new plan

As JPM 2024 winds down, some health tech firms project optimism

FDA authorizes Novavax’s updated Covid

DeSantis can now import cheaper drugs. But will Biden get credit?

Why age limits for politicians are a terrible idea

FDA authorizes Novavax’s updated Covid

leisure time

hotspot

hotspot

hotspot